Robotic gynaecological surgery using Senhance® robotic platform: Single centre experience with 100 cases

Šiaulys, Raimondas; Klimašauskienė, Vita; Janušonis, Vinsas; Ezerskiene, Viktorija; Dulskas, Audrius; Samalavičius, Narimantas Evaldas

doi:10.1016/j.jogoh.2020.102031

Cited by 14 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three complications occurred during 30 days after the operation [44]. The authors concluded that the Senhance system is safe and feasible for use in MAS [44][45][46].…”

Section: Discussionmentioning

confidence: 85%

“…Two intraoperative complications were observed, and one patient was readmitted in the early postoperative period due to severe vaginal bleeding [45]. Three complications occurred during 30 days after the operation [44]. The authors concluded that the Senhance system is safe and feasible for use in MAS [44][45][46].…”

Section: Discussionmentioning

confidence: 90%

“…The mean duration of the patients' hospital stay was 4 ± 2.3 days, range 1-14 days. Six (6%) conversions were reported: one to laparoscopy and five to open surgery [44]. Two intraoperative complications were observed, and one patient was readmitted in the early postoperative period due to severe vaginal bleeding [45].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the Versius Robotic Surgical System in Minimal Access Surgery: A Systematic Review

Alkatout

Salehiniya

Allahqoli

2022

JCM

View full text Add to dashboard Cite

Background: Despite the superiority of minimal access surgery (MAS) over open surgery, MAS is difficult to perform and has a demanding learning curve. Robot-assisted surgery is an advanced form of MAS. The Versius® surgical robot system was developed with the aim of overcoming some of the challenges associated with existing surgical robots. The present study was designed to investigate the feasibility, clinical safety, and effectiveness of the Versius system in MAS. Materials and Methods: A comprehensive search was carried out in the Medline, Web of Science Core Collection (Indexes = SCI-EXPANDED, SSCI, A & HCI Timespan), and Scopus databases for articles published until February 2022. The keywords used were Versius robot, visceral, colorectal, gynecology, and urologic surgeries. Articles on the use of the Versius robot in minimal access surgery (MAS) were included in the review. Results: Seventeen articles were reviewed for the study. The investigation comprised a total of 328 patients who had been operated on with this robot system, of which 48.3%, 14.2%, and 37.5% underwent colorectal, visceral, and gynecological procedures, respectively. Postoperative and major complications within 30 days varied from 7.4% to 39%. No major complications and no readmissions or reoperations were reported in visceral and gynecological surgeries. Readmission and reoperation rates in colorectal surgeries were 0–9%. Some procedures required conversion to conventional laparoscopic surgery (CLS) or open surgery, and all procedures were completed successfully. Based on the studies reviewed in the present report, we conclude that the Versius robot can be used safely and effectively in MAS. Conclusions: A review of the published literature revealed that the Versius system is safe and effective in minimal access surgery. However, the data should be viewed with caution until randomized controlled trials (RCTs) have been performed. Studies on the use of this robotic system in oncological surgery must include survival as one of the addressed outcomes.

show abstract

“…Three complications occurred during 30 days after the operation [44]. The authors concluded that the Senhance system is safe and feasible for use in MAS [44][45][46].…”

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Assessment of the Versius Robotic Surgical System in Minimal Access Surgery: A Systematic Review

Alkatout

Salehiniya

Allahqoli

2022

JCM

View full text Add to dashboard Cite

show abstract

“…With the advancement of surgical robot technology, an increasing number of surgical robot platforms have been developed and applied in clinical practice in different countries, such as the REVO-I, Senhance, Versius and TELELAP ALF-X surgical robotic systems. [8][9][10][11][12][13] Recently, a new robotic platform called KD-SR-01 (Suzhou Kangduo Robot Co., Ltd.) was developed in China. The KD-SR-01 system has successfully completed PN in animal experiments.…”

Section: Introductionmentioning

confidence: 99%

“…In the last 2 decades, the da Vinci surgical robotic system (Intuitive Surgical) has dominated the surgical robot market given its benefits of three‐dimensional (3D) magnified vision and flexible endowrists. With the advancement of surgical robot technology, an increasing number of surgical robot platforms have been developed and applied in clinical practice in different countries, such as the REVO‐I, Senhance, Versius and TELELAP ALF‐X surgical robotic systems 8–13 …”

Section: Introductionmentioning

confidence: 99%

Partial nephrectomy through retroperitoneal approach with a new surgical robot system, KD‐SR‐01

Wang

Fan

Shen

et al. 2021

Robotics Computer Surgery

View full text Add to dashboard Cite

Background: To present our experiences with partial nephrectomy (PN) through retroperitoneal approach (RP) with the Kangduo robotic system.Methods: From December 2020 to February 2021, the perioperative data of 11 patients underwent PN through RP with the Kangduo robotic system were collected prospectively.Results: For the R.E.N.A.L. nephrometry score, 72.7% of patients had a low score (4-6) and 27.3% of patients had a medium score (7-9). Seven tumours were posterior (P), four tumours were on the midline (X). All procedures were completed successfully. The median warm ischemia time was 18.5 (IQR, 13.7-21.0) min. None of the patients had positive surgical margins at definitive histology (all pT1a). No high-grade perioperative complications or device-related adverse events occurred.At a mean follow-up of 8 � 0.8 months, no complications occurred in all patients.

show abstract

Colorectal Surgery with the Senhance Digital Laparoscopic Platform

Darwich

Stephan

2022

Robotic Colorectal Surgery

View full text Add to dashboard Cite

Robotic gynaecological surgery using Senhance® robotic platform: Single centre experience with 100 cases

Cited by 14 publications

References 17 publications

Assessment of the Versius Robotic Surgical System in Minimal Access Surgery: A Systematic Review

Assessment of the Versius Robotic Surgical System in Minimal Access Surgery: A Systematic Review

Partial nephrectomy through retroperitoneal approach with a new surgical robot system, KD‐SR‐01

Colorectal Surgery with the Senhance Digital Laparoscopic Platform

Contact Info

Product

Resources

About